Internal Radiotherapy Market - A Global and Regional Analysis: Focus on Type, Application, End User, and Country-Level Analysis - Analysis and Forecast, 2025-2035

Introduction to Internal Radiotherapy Market

Internal radiotherapy, also known as brachytherapy, is a specialized form of radiation therapy used to treat various types of cancer. Unlike external beam radiation therapy (EBRT), which delivers radiation from outside the body, internal radiotherapy places radioactive sources directly inside or near the tumor. This allows for a highly targeted and localized dose of radiation, minimizing damage to surrounding healthy tissues.

The internal radiotherapy market is witnessing significant advancements, driven by increasing cancer prevalence, technological innovations, and the rising demand for minimally invasive treatment solutions. Internal radiotherapy, particularly brachytherapy, is gaining traction as an effective treatment modality due to its ability to deliver highly localized radiation while minimizing damage to surrounding healthy tissues. The market is experiencing steady growth as healthcare providers adopt high-dose-rate (HDR) and low-dose-rate (LDR) brachytherapy for cancers such as prostate, cervical, breast, and lung cancer. With advancements in radioactive isotope technology, image-guided brachytherapy, and AI-assisted radiation planning, the global internal radiotherapy market is poised for substantial expansion by 2035. The growing adoption of robot-assisted brachytherapy procedures, patient-specific radiation dosing, and real-time imaging techniques is enhancing treatment precision and improving patient outcomes.

The rising global incidence of cancer, particularly prostate, breast, and cervical cancers, is driving the demand for effective radiation therapy solutions. According to the World Health Organization (WHO), cancer is one of the leading causes of death globally, with an estimated 10 million deaths in 2020 alone. As the global population continues to age, the number of cancer cases is expected to rise, leading to a greater need for therapies such as internal radiotherapy. The American Cancer Society estimates that by 2024, nearly 1.9 million new cancer cases will be diagnosed in the U.S. alone, further increasing the demand for targeted treatments such as brachytherapy.

In addition, there has been a substantial increase in investment in oncology research and the development of advanced radiation technologies. Leading players such as Elekta AB, Siemens Healthineers AG, and Terumo Corporation are heavily investing in R&D to improve the precision and accessibility of their radiation therapy systems. For instance, Elekta AB recently introduced the Evo linear accelerator, equipped with AI-enhanced imaging, which significantly improves tumor targeting and treatment precision. Therefore, the development of such products is further propelling the market.

Emerging markets in the Asia-Pacific, Latin America, and Middle East regions represent substantial growth opportunities for the internal radiotherapy market due to the rising incidence of cancer, improving healthcare infrastructure, and increasing awareness about advanced treatment options. In Asia-Pacific, countries such as India, China, and Japan are experiencing significant healthcare advancements, with expanding access to cancer care and technologies such as brachytherapy. The growing adoption of minimally invasive treatment options is further spurred by the increasing prevalence of cancers such as prostate, breast, and cervical cancers. Further, These regions are benefiting from government initiatives, better healthcare financing, and partnerships with international medical device manufacturers, driving the adoption of internal radiotherapy solutions and paving the way for further market expansion in the coming years.

However, The internal radiotherapy market faces several challenges despite its technological advancements and growing adoption. One of the primary hurdles is the high cost of treatment and infrastructure, which limits accessibility, especially in developing regions with constrained healthcare budgets. Additionally, stringent regulatory approvals and complex compliance requirements pose barriers to market entry for new players and delay product launches. Thus, the aforementioned factors remain challenges for market growth.

Leading players in the internal radiotherapy market are employing various strategies to strengthen their competitive position. For instance, in May 2024, Elekta AB introduced the Evo linear accelerator (linac), a CT-Linac equipped with high-definition AI-enhanced imaging. This innovation enables both offline and online adaptive radiation therapy, as well as improved standard image-guided treatments. Adding to this, Varian, a subsidiary of Siemens Healthineers, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its TrueBeam and Edge radiotherapy systems featuring the HyperSight imaging solution. This approval signifies a step forward in providing advanced imaging capabilities for precise tumor targeting. Such strategic initiatives reflect the industry's commitment to advancing internal radiotherapy technologies and expanding global access to cutting-edge cancer treatment solutions.

Key players in the market: are Elekta AB, Siemens Healthineers AG, Terumo Corporation, BEBIG Medical GmbH, Theragenics Corporation, Best Medical International, GT Medical Technologies, and Boston Scientific Corporation. among others.

Market Segmentation:

Segmentation 1: by Type

Brachytherapy
Systemic Radiation Therapy

Brachytherapy to Lead the Global Internal Radiotherapy Market (by Type)

The brachytherapy segment is experiencing significant growth within the internal radiotherapy market, driven by advancements in treatment precision, increasing cancer cases, and the rising demand for minimally invasive therapies. Brachytherapy, due to its ability to deliver high doses of radiation directly to the tumor while minimizing exposure to surrounding healthy tissues, is increasingly being recognized as a preferred treatment option for cancers such as prostate, cervical, breast, and lung cancers. Additionally, the growing incidence of prostate cancer, particularly in the aging population, is a key factor contributing to the increasing demand for prostate brachytherapy, which is one of the most commonly performed forms of brachytherapy. The cost-effectiveness of brachytherapy, combined with its ability to deliver localized radiation with fewer side effects compared to external radiation, has made it an attractive option for both clinicians and patients.

Segmentation 2: by Application

Prostate
Breast
Head and Neck
Others

Segmentation 3: by End User

Hospital
Specialty Clinic

Hospitals to Lead the Global Internal Radiotherapy Market (by End User)

Hospitals are the primary adopters of internal radiotherapy due to the high patient volume and the necessity for precise diagnostics. Hospitals are equipped with state-of-the-art equipment, such as radioactive isotope sources, CT/MRI-guided radiation systems, and delivery devices such as balloon catheters and needles. This equipment allows for the precise placement of radioactive materials within or near tumors, ensuring targeted treatment that minimizes damage to healthy tissues. Additionally, hospitals offer radiation therapy suites, sterile environments, and patient monitoring systems, ensuring the safe administration of internal radiotherapy. Further, the growing demand for minimally invasive treatment options, along with continued advancements in imaging and radiation delivery systems, will solidify hospitals' role as leading providers of internal radiotherapy in the global healthcare landscape.

Segmentation 4: by Region

North America
Europe
Asia Pacific
Latin America
Rest of World

North America to Lead the Global Internal Radiotherapy Market (by Region)

North America leads the internal radiotherapy market, primarily driven by advanced healthcare infrastructure, high cancer incidence rates, and strong regulatory support. The region, especially the U.S. and Canada, is home to some of the most innovative medical device manufacturers and cutting-edge radiation therapy technologies, making it a global leader in the adoption of internal radiotherapy solutions. In the U.S., the high prevalence of cancer, particularly prostate, breast, and cervical cancers, has spurred demand for precise, minimally invasive treatments. Moreover, the FDA's favourable regulatory framework for medical devices and therapies accelerates the approval and market introduction of new products, further supporting market growth.

*PDF email from publisher allows for 1-3 users, with permission to print*

Please Note: It will take 7-10 business days to complete the report upon order confirmation.